Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 9

Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

March 21, 2025

Benjamin P. Levy, MD, Misty D. Shields, MD, PhD

Panelists discuss how MARIPOSA-2 (Popat S, et al, ESMO 2024) and the September 2024 FDA approval of amivantamab plus chemo as a second-line option highlight advances in non–small cell lung cancer (NSCLC) treatment. Strategies involve sequencing with emerging therapies like HERTHENA-Lung01, addressing resistance, and central nervous system (CNS) metastases. The complete response letter (CRL) for HER3-DXd and the shift in biologics license application (BLA) status for Dato-DXd from TROPION-Lung05 (Lisberg A, et al, ASCO 2024) will shape clinical practices and resistance management moving forward.

EP. 1: An Expert Insights on Recent Advancements in LS-SCLC

EP. 2: The Key Updates in the Treatment of ES-SCLC

EP. 3: An Expert Perspectives on Tarlatamab in ES-SCLC

EP. 4: Looking Ahead With SCLC: ADCs and Other Novel Agents

EP. 5: The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP. 6: Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP. 7: The New Targeted Approaches in Unresectable Early-Stage NSCL

EP. 8: Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

Now Viewing

EP. 9: Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP. 10: Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations

EP. 11: The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP. 12: Tailoring Immunotherapy Strategies for the Advanced NSCLC

Video content above is prompted by the following:

Briefly comment on MARIPOSA-2 (Popat S, et al. ESMO 2024. Abs LBA54)andthe recentFDA approval (September 2024) of combination amivantamab plus chemo as a second-line treatment option.
How are you integrating the MARIPOSA-2 regimen into your clinical practice, and how do you sequence it with other available therapies?
If you use MARIPOSA up front, what is your strategy in the second-line setting?
How do emerging data from the HERTHENA-Lung01 study (Johnson M, et al. ESMO 2023. Abs 1319MO) inform your approach to managing treatment resistance management and CNS metastases?
How might the recent CRL for HER3-DXd impact clinical practice over the next year?
What are your perceptions of the latest data from TROPION-Lung05 and the recent shift in BLA status for Dato-DXd?(Lisberg A, et al. ASCO 2024. Abs 8593)